You are here

  • Home
  • Archive
  • Volume 22, Issue 4
  • Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Article Text

Article menu
Download PDFPDF
Aetiology/Harm
Cohort study
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

https://doi.org/10.1136/ebmed-2017-110764

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding JMR-C is supported by Instituto Murciano de Investigación Biosanitaria (IMIB16/AP/01/06) and has received a grant from Sociedad Española de Trombosis y Hemostasia (grant for short international training stays 2016).

    • Competing interests GYHL is a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi Sankyo. No fees are received personally.

    • Provenance and peer review Commissioned; internally peer reviewed.